Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).

Romualdi E, Donadini MP, Ageno W.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):841-4. doi: 10.1586/erc.11.62.

PMID:
21809964
2.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.

3.

Rivaroxaban, the first oral, direct factor Xa inhibitor.

Fassiadis N.

Expert Opin Pharmacother. 2009 Dec;10(18):2945-6. doi: 10.1517/14656560903413559.

PMID:
19925048
4.

Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.

Yong CM, Boyle AJ.

Curr Vasc Pharmacol. 2010 Jan;8(1):5-11. Review.

PMID:
19485937
5.

Rivaroxaban, an oral direct factor Xa inhibitor.

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.

Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . Review.

PMID:
18491993
6.

[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].

Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, Sié P.

J Mal Vasc. 2012 Dec;37(6):300-10. doi: 10.1016/j.jmv.2012.09.003. Epub 2012 Nov 2. French.

PMID:
23122646
7.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
8.

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

Cohen AT, Dobromirski M.

Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Review.

PMID:
22371186
9.

Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.

Morell J, Sullivan B, Khalabuda M, McBride BF.

J Clin Pharmacol. 2010 Sep;50(9):986-1000. doi: 10.1177/0091270009355814. Epub 2010 Feb 2.

PMID:
20124518
10.
11.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

12.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

13.

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators.

Circulation. 2006 Nov 28;114(22):2374-81. Epub 2006 Nov 20.

14.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

15.

[Rivaroxaban: mode of action].

Drouet L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S9-15. doi: 10.1016/S0750-7658(08)75141-4. Review. French.

PMID:
19185786
16.

Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.

Huisman MV, Bounameaux H.

Semin Vasc Med. 2005 Aug;5(3):276-84.

PMID:
16123915
18.

Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators.

Circulation. 2007 Jul 10;116(2):180-7. Epub 2007 Jun 18.

19.

Factor Xa inhibitors--new anticoagulants for secondary haemostasis.

Perzborn E.

Hamostaseologie. 2009 Aug;29(3):260-7.

PMID:
19644596
20.

[Rivaroxaban (Xarelto): efficacy and safety].

Rosencher N, Arnaout L, Chabbouh T, Bellamy L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7. doi: 10.1016/S0750-7658(08)75143-8. Review. French.

PMID:
19185784
Items per page

Supplemental Content

Write to the Help Desk